Clinical and histological impact of previous hepatitis B virus infection in patients with chronic hepatitis C

Liver International

Volumn 29, Issue 1, 2009, Pages 133-140

  Carvalho Filho, Roberto J ^a,b   De Lucca Schiavon, Leonardo ^a   Narciso Schiavon, Janaína L ^a   Sampaio, Juliana P ^a   Lanzoni, Valéria P ^a   Gomes Ferraz, Maria L ^a   Benedito Silva, Antonio E ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Co infection; Hepatitis B; Hepatitis C; Liver fibrosis; Occult hepatitis B; Previous hepatitis B

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INTERFERON; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; INFECTION RATE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; VIRUS CARRIER; VIRUS REPLICATION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; STATISTICS, NONPARAMETRIC;

EID: 57749200949     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01786.x     Document Type: Article

References (50)

1. WHO. Global Surveillance and Control of Hepatitis C. Report of a WHO consultation organized in collaboration with The Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Wasley A, Alter MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
3. Sociedade Brasileira de Hepatologia (SBH). Relatório do Grupo de Estudo da SBH: Epidemiologia da infecção pelo vírus da hepatite C no Brasil. Gastrenterologia Endoscopia Digestiva 1999; 18: 53-8.
4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56.
5. Seeff L. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
6. Poynard T, Yuen M-F, Ratziu V, Lai C-L. Viral hepatitis C. Lancet 2003; 362: 2095-100.
7. Leandro G, Mangia A, Hui J, et al. HCV Meta-Analysis of Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
8. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antige: Clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
9. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
10. Stransky J, Malina L, Cieslarova B, et al. Overt and hidden co-infection with hepatitis B and C viruses in chronic liver disease and Porphyria cutanea tarda. Acta Virol 2000; 44: 23-8.
11. De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-36.
12. Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001; 63: 220-7.
13. Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/ HGV on hepatocellular carcinomas in Europe: Results of a European concerted action. J Hepatol 1998; 29: 173-83.
14. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.
15. Sagnelli E, Coppola N, Scolastico C, et al. HCV genotype and "silent" HBV co-infection: Two main risk factors for a more severe liver disease. J Med Virol 2001; 64: 350-5.
16. Giannini E, Ceppa P, Botta F, et al. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients. Liver Int 2003; 23: 12-8.
17. Imazeki F, Yokosuka O, Fukai K, et al. Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2003; 48: 1786-92.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
19. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
20. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
21. Khan MH, Farrell GC, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-20.
22. Poynard T, Ratziu V, Benhamou Y, et al. Natural history of HCV infection. Baillière's Clin Gastroenterol 2000; 14: 211-28.
23. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904-9.
24. Lagging LM, Westin J, Svensson E, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002; 22: 136-44.
25. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
26. Focaccia R, da Conceicao OJ, Sette H, et al. Estimated prevalence of viral hepatitis in the general population of the municipality of Sao Paulo, measured by a serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998; 2: 269-84.
27. Goncales FL Jr, Pedro RJ, da Silva LJ, et al. Post-transfusional hepatitis in the city of Campinas, SP, Brazil. II. Presence of anti-HBc and anti-HCV antibodies in blood donor candidates and occurrence of post-transfusional hepatitis C in recipients of blood or derivates. Rev Inst Med Trop Sao Paulo 1993; 35: 63-71.
28. Uchida T, Kaneita Y, Gotoh K, et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: Probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997; 52: 399-405.
29. Koike K, Kobayashi M, Gondo M, et al. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998; 54: 249-55.
30. Marusawa H, Osaki Y, Kimura T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut 1999; 45: 284-8.
31. Hope VD, Judd A, Hickman M, et al. Prevalence of hepatitis C among injection drug users in England and Wales: Is harm reduction working? Am J Public Health 2001; 91: 38-42.
32. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002; 97: 2408-14.
33. Kao J-H, Chen P-J, Lai M-Y, Chen D-S. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 4068-71.
34. Myers RP, Thibault V, Poynard T. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C. J Viral Hepat 2003; 10: 103-10.
35. Fabris P, Brown D, Tositti G, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004; 29: 160-6.
36. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004; 11: 358-65.
37. Torbenson M, Kannangai R, Astemborski J, et al. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39: 51-7.
38. Wedemeyer H, Cornberg M, Tegtmeyer B, et al. Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. Clin Microbiol Infect 2004; 10: 70-2.
39. Hasegawa I, Orito E, Tanaka Y, et al. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-átherapy for patients with chronic hepatitis C. Liver Int 2005; 25: 247-53.
40. Shev S, Dhillon AP, Lindh M, et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver 1997; 17: 215-23.
41. Serfaty L, Chazouilleres O, Poujol-Robert A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study. Hepatology 1997; 26: 776-9.
42. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
43. Mathurin P, Thibault V, Kadidja K, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, D) hepatic infections. J Viral Hepat 2000; 7: 15-22.
44. Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36: 1285-91.
45. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000; 32: 1106-10.
46. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/ hepatitis C virus-coinfected patients. Hepatology 2006; 43: 100-7.
47. Schuttler CG, Fiedler N, Schmidt K, et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002; 37: 855-62.
48. Shih CM, Lo SJ, Miyamura T, et al. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993; 67: 5823-32.
49. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16: 636-40.
50. Kaklamani E, Trichopoulos D, Tzonou A, et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-6.